Diagnosis and Management of Pituitary Tumors

CHAPTER 14 / MEDICAL THERAPY 265184. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G andthe Italian Multicenter Octreotide Study Group. Effect of treatmentwith octreotide in acromegalic patients—a multicenter Italianstudy. Eur J Endocrinol 1995;133:430–439.185. Van der Lely AJ, Harris AG, Lamberts SWJ. The sensitivity ofgrowth hormone secretion to medical treatment in acromegalicpatients: influence of age and sex. Clin Endocrinol 1992;37:181–185.186. Koop BL, Harris AG, Ezzat S. Effect of octreotide on glucosetolerance in acromegaly. Eur J Endocrinol 1994;130:581–586.187. Grunstein RR, Ho KKY, Sullivan CE. Sleep apnea in acromegaly.Ann Intern Med 1991;115:527–532.188. Grunstein RR, Ho KKY, Sullivan CE. Effect of octreotide, a somatostatinanalog, on sleep apnea in patients with acromegaly. AnnIntern Med 1994;121:478–483.189. Thuesen L, Christensen SE, Weeke J, Orskov H, Henningsen P.The cardiovascular effects of octreotide treatment in acromegaly:an echocardiographic study. Clin Endocrinol 1989;30:619–625.190. Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects ofthe somatostatin analog octreotide in acromegaly. Ann Intern Med1990;113:921–925.191. Paunovi´c VR, Popovi´c V. The development of dependence to anoctapeptide somatostatin analog: contribution of the study ofsomatostatin analgesia. Biol Psychiatry 1989;26:97–101.192. Pascual J, Freijanes J, Berciano J, Pesquera C. Analgesic effect ofoctreotide in headache associated with acromegaly is not mediatedby opioid mechanisms. Case report. Pain 1991;46:341–344.193. Stevenaert A, Beckers A. Presurgical octreotide treatment inacromegaly. Acta Endocrinol 1993;129 (Suppl 1):18–20.194. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC.Depot long-acting somatostatin analog (Sandostatin-LAR) is aneffective treatment for acromegaly. J Clin Endocrinol Metab1995;80:3267–3272.195. Grass P, Marbach P, Bruns C, et al. Sandostatin LAR (microencapsulatedoctreotide acetate) in acromegaly: pharmacokineticsand pharmacodynamics relationships. Metabolism 1996;45(suppl 1):27–30.196. Lancranjan I, Atkinson AB, and the Sandostatin LAR Group.Results of a European Multicentre Study with Sandostatin LAR inacromegalic patients. Pituitary 1999;1:105–114.197. Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, et al.Pharmacokinetics and efficacy of a long-acting formulation of thenew somatostatin analog BIM 23014 in patients with acromegaly.J Clin Endocrinol Metab 1993;76:721–727.198. Motange I, De Boisvilliers F, Chanson P, Lucas B, Dewailly D,Catus F, et al. Slow release lanreotide treatment in acromegalicpatients previously normalized by octreotide. J Clin EndocrinolMetab 1994;79:145–151.199. Newman CB. Medical therapy for acromegaly. Endocrinol MetabClin N Amer 1999;28:171–190.200. Ho PJ, Boyajy LD, Greenstein E, Barkan AL. Effect of chronicoctreotide treatment on intestinal absorption in patients withacromegaly. Dig Dis Sci 1993;38:309–315.201. Plöckinger U, Dinemann D, Quabbe H-J. Gastrointestinal sideeffectsof octreotide during long term treatment of acromegaly. JClin Endocrinol Metab 1990;71:1658–1662.202. Anderson JV, Catnach S, Lowe DG, Fairclough PD, Besser GM,Wass JAH. Prevalence of gastritis in patients with acromegaly:untreated and during treatment with octreotide. Clin Endocrinol1992;37:227–232.203. Hopman WPM, van Liessum PA, Pieters GFFM, Jansen JBMJ,Lamers CBHW, Smals AGH, et al. Postprandial gallbladdermotility and plasma cholecystokinin at regular time intervals afterinjection of octreotide in acromegalics on long-term treatment.Dig Dis Sci 1992;37:1685–1690.204. Eastman RC, Arakaki RF, Shawker T, Schock R, Roach P, ComiRJ, et al. A prospective examination of octreotide-induced gallbladderchanges in acromegaly. Clin Endocrinol 1992;36:265–269.205. Catnach SM, Anderson JV, Fairclough PD, Trembath RC, WilsonPAJ, Parker E, et al. Effect of octreotide on gall stone prevalenceand gall bladder motility in acromegaly. Gut 1993;34:270–273.206. Stolk MFJ, van Erpecum KJ, Koppeschaar JPF, de Bruin WI,Jansen JBMJ, Lamers CBHW, et al. Postprandial gall bladdermotility and hormone release during intermittent and continuoussubcutaneous octreotide treatment in acromegaly. Gut 1993;34:808–813.207. Shi Y-F, Zhu X-F, Harris AG, Zhang J-X, Dai Q. Prospective studyof the long-term effects of somatostatin analog (octreotide) ongallbladder function and gallstone formation in chinese acromegalicpatients. J Clin Endocrinol Metab 1993;76:32–37.208. Tauber JP, Poncet MF, Harris AG, Barthel HR, Simonetta-Chateauneuf C, Buscail L, et al. The impact of continuous subcutaneousinfusion of octreotide on gallstone formation in acromegalicpatients. J Clin Endocrinol Metab 1995;80:3262–3266.209. Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G,Petroncini M, et al. Medical treatment of acromegaly with SMS201-995, a somatostatin analog: a comparison with bromocriptine.J Clin Endocrinol Metab 1987;64:447–453.210. Fløgstad AK, Halse J, Grass P, Abisch E, Djøseland O, Kutz K, etal. A comparison of octreotide, bromocriptine, or a combination ofboth drugs in acromegaly. J Clin Endocrinol Metab 1994;79:462–466.211. Lamberts SWJ, Zeens M, Verschoor L, del Pozo E. A comparisonamong the growth hormone-lowering effects in acromegaly of thesomatostatin analog SMS 201–995, bromocriptine, and the combinationof both drugs. J Clin Endocrinol Metab 1986;63:16–19.211a. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegalywith pegvisomant, a genetically-engineered human growthhormone receptor antagonist. N Engl J Med. In Press.212. Feldman D. Ketoconazole and other imidazole derivatives asinhibitors of steroidogenesis. Endocr Rev 1986;7:409–420.213. Stalla GK, Stalla J, Huber M, Loeffler J-P, Hollt V, van Werder K,et al. Ketoconazole inhibits corticotropic cell function in vitro.Endocrinology 1988;122:618–623.214. Stalla GK, Stalla J, von Werder K, Müller OA, Gerzer R, Höllt V,et al. Nitroimidazole derivatives inhibit anterior pituitary cell functionapparently by a direct effect on the catalytic subunit of theadenylate cyclase holoenzyme. Endocrinology 1989;125:699–706.215. Reina LJ, Leal-Cerro A, Garcia J, Garcia-Luna PP, Astorga R,Bernal G. In vitro effects of ketoconazole on corticotrope cellmorphology and ACTH secretion of two pituitary adenomasremoved from patients with Nelson’s syndrome. Acta Endocrinol1989;121:185–190.216. Sonino N. The use of ketoconazole as an inhibitor of steroid production.N Engl J Med 1987;317:812–818.217. Cerdas S, Billaud L, Guilhaume B, Laudat MH, Bertagna X, LutonJP. Effects a court terme due ketoconazole dans les syndromes deCushing. Ann d’Endocrinologie 1989;50;489–496.218. Tabarin A, Navarranne A, Guérin J, Corcuff J-B, Parneix M, RogerP. Use of ketoconazole in the treatment of Cushing’s disease andectopic ACTH syndrome. Clin Endocrinol 1991;34:63–69.219. Sonino N, Boscaro M, Paoletta A, Manetero F, Ziliotto D.Ketoconazole treatment in Cushing’s syndrome: experience in 34patients. Clin Endocrinol 1991;35:347–352.219a. Invitti C, Giraldi P, de Martin M, Cavagnini F, and The StudyGroup of the Italian Society of Endocrinology on the Pathophysiologyof the Hypothalamic-Pituitary-Adrenal Axis. Diagnosis andmanagement of Cushing’s syndrome: results of an ItalianMulticenter Study. J Clin Endocrinol Metab 1999;84:440–448.219b. Sonino N, Boscaro M. Medical therapy for Cushing’s disease.Endocrinol Metab Clin N Amer 1999;28:211–222.220. Krieger DT, Amorosa L, Linick F. Cyproheptadine-inducedremission of Cushing’s disease. N Engl J Med 1975;293:893–896.221. Middler SA. Cyproheptadine for pituitary disorders. N Engl J Med1976;295:394.222. Barnes P, Shaw K, Ross E. Cushing’s disease: successful treatmentwith cyproheptadine. Lancet 1977;1:1148–1149.223. Krieger DT, Condon EM. Cyproheptadine treatment of Nelson’ssyndrome: restoration of plasma ACTH circadian periodicity andreversal of response to TRF. J Clin Endocrinol Metab 198;46:349–352.